Delisting risk
Actinium Pharmaceuticals
Develops targeted radiotherapies for cancer and transplant conditioning.
$1.02
After-hours close+0.01 (+0.99%)
At close$1.01(+1.00%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 16.90%Insiders —
Shares outstanding 31.37M · Float 31.19M · 99.4% free float
Institutions13F, as of Mar 31, 2026
55 holders · 5.30M shares · 7 new positions · 19 increased · 14 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.26M | 4.00% | +1.26Mnew | May 15, 2026 |
| Acadian Asset Management LLC | 600.8K | 1.91% | −5.5K | May 13, 2026 |
| Millennium Management LLC | 564.6K | 1.80% | −37.0K | May 15, 2026 |
| Renaissance Technologies LLC | 471.6K | 1.50% | +80.8K | May 14, 2026 |
| BlackRock, Inc. | 371.2K | 1.18% | +4.3K | May 13, 2026 |
| Two Sigma Investments, LP | 337.2K | 1.07% | +127.5K | May 15, 2026 |
| Geode Capital Management, LLC | 336.1K | 1.07% | +7.1K | May 15, 2026 |
| Gagnon Securities LLC | 201.3K | 0.64% | −507 | Apr 22, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| The Vanguard Group | 5.21% | 1.63M | 13G | Nov 4, 2024 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.